Standout Papers

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell... 2021 2026 2022 2024199
  1. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial (2021)
    Nasser K. Altorki, Timothy E. McGraw et al. The Lancet Oncology

Immediate Impact

6 by Nobel laureates 1 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
1 intermediate paper

Works of C Spinelli being referenced

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
C Spinelli 113 267 57 205 20 456
Masayuki Okido 164 262 67 139 31 505
Elisa Bacillo 92 207 43 240 18 459
David H. Hwang 66 125 95 207 21 468
Shumpei Matsuura 41 153 67 118 19 483
Shuai Wang 131 244 37 98 24 438
Claudia Parolini 64 135 48 143 18 451
Xueyan Wang 73 130 51 114 32 478
Thomas Jiborn 49 117 64 283 15 426
Arimi Ishikawa 140 104 20 103 23 392
Yasuhiro Koikawa 93 160 43 215 22 474

All Works

Loading papers...

Rankless by CCL
2026